More than 90 percent of new crown patients in Iceland have their antibody levels rising after diagnosis, and then remain stable for up to four months, according to a new study. The findings were published September 1 in the New England Journal of Medicine. To find out how many people in Iceland are infected with the new coronary virus and how well patients are immune after recovery, researchers tested more than 30,000 Icelanders for antibody levels.
According to the results of the survey, about 1% of iceland’s population is infected with the new coronary virus. Of those infected, 56 per cent had been tested and confirmed to be infected by PCR laboratories, another 14 per cent had not been formally diagnosed but had been quarantined for exposure to the virus, and the remaining 30 per cent had tested positive for antibodies that showed they had previously been infected.
The researchers reported that 91 percent of the 1,215 infected people confirmed by PCR tests had their antibody levels rising in the first two months after diagnosis and remaining stable two months later.
The study focused only on subjects from one country in Iceland, and the results may be different in other parts of the world with diverse populations, the report said.
In previous studies, antibody levels in patients with new coronary pneumonia dropped sharply a few months after infection, raising questions about the duration of immunity that the infection might provide.
Kari Stefansson, chief executive of deCode Genetics, the genetic analysis testing company that conducted the study, said the new findings could have an impact on the risk of re-infection with new coronary pneumonia and the durability of the new crown vaccine.
An editorial published at the same time as the study warned that it was unclear whether antibodies in patients with healthy new crowns would protect them from reinserted.